trending Market Intelligence /marketintelligence/en/news-insights/trending/kjrrnyybnm8tbupmyp8mnq2 content esgSubNav
In This List

Zymeworks licenses antibody platforms to Daiichi Sankyo

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Zymeworks licenses antibody platforms to Daiichi Sankyo

Canada's Zymeworks Inc. agreed to license two antibody platforms to Japan's Daiichi Sankyo Co. Ltd.

Under the agreement, Zymeworks will receive US$18 million up front for its Azymetric and Efect platforms, which enable the customization of certain antibody therapies. Daiichi Sankyo also agreed to pay up to US$466.7 million in milestone payments and double-digit tiered royalties on global product sales.

The agreement expands a 2016 cross-licensing and collaboration agreement between the companies.